Alere fell 3 percent after it sued Abbott to compel it to get all antitrust approvals required to complete its $5.8 billion merger. » Read More
A Yale study found that e-cig users who ingested alcohol vapor had worse motor skills despite not feeling drunk.
While President Barack Obama delivered his final State of the Union address on Tuesday, Vice President Joe Biden revealed his cancer "moonshot."
While the biotech sector has been under fire for high drug prices, Biotech CEO says that it brings innovations.
Stretchy and durable smart garments could soon help wearers track their activity and vital signs.
The Facebook founder and CEO dropped himself into the riotous social media debate over childhood vaccines.
"We have to focus on prevention because we weren't designed to go into our ninth or 10th decade," says David Agus, doctor to the late Steve Jobs.
Pandemics are a neglected risk to lives and economies that could costs trillions of dollars, says a new report.
Drug costs continue to rise and will only get worse moving forward, one expert contended Tuesday.
Investors who backed a biotech company led by Martin Shkreli are suing to get back the $5.4 million they invested just hours before his arrest.
A former researcher says the pharma giant fired him for raising red flags about statistical problems in tobacco-cessation studies.
Check out Prothena CEO Dale Schenk's revealing update on the state of the company's pipeline and its prospects.
Biotech CEOs say that drug pricing needs to be balanced enough to support research and development.
Biotech stocks endured a rough Monday, and struggles may continue throughout the year for the high-growth sector, one trader said.
Several factors are being overlooked when discussing drug pricing in the U.S., three pharma CEOs say.
Celgene Chairman and CEO Bob Hugin, discusses his outlook for the health care industry, and M&A in the space.
Discussing research and development in the biotech space, and drug pricing responsibly, with Johnson & Johnson CEO Alex Gorsky.
Get the best of CNBC in your inbox